Leung Sing-Fai, Lo Y M Dennis, Chan Anthony T C, To Kai-Fai, To Edward, Chan Lisa Y S, Zee Benny, Huang Dolly P, Johnson Philip J
Department of Clinical Oncology, The Chinese University of Hong Kong, Hong Kong SAR, China.
Clin Cancer Res. 2003 Aug 15;9(9):3431-4.
The purpose of this research was to compare the sensitivities of plasma EBV DNA in detection of postirradiation locally recurrent nasopharyngeal carcinoma (NPC), postirradiation distant metastatic NPC, and radiation-naïve NPC.
Twenty-four patients with postirradiation local recurrence of NPC were assessed for plasma EBV DNA levels by a real-time quantitative PCR system. The results were compared with those of a cohort of 140 patients with newly diagnosed NPC and with those of 25 patients with distant metastatic relapse. EBV-encoded RNA positivity was also assessed in locally recurrent tumors and newly diagnosed tumors with undetectable plasma EBV DNA levels.
Postirradiation locally recurrent tumors were associated with a significantly lower rate of detectable plasma EBV DNA compared with radiation-naïve tumors of comparable stage [stage I-II tumors: 5 of 12 (42%) versus 47 of 51 (92%), P = 0.0002; stage III-IV tumors: 10 of 12 (83%) versus 88 of 89 (99%), P = 0.01; Fisher's exact test], and compared with distant metastatic recurrences [15 of 24 (63%) versus 24 of 25 (96%), P < 0.02; Fisher's exact test]. The median EBV DNA level in patients with detectable EBV DNA was also significantly lower in locally recurrent tumors than in radiation-naïve tumors. All of the tissue samples of tumors associated with undetectable EBV DNA levels, where available, were EBV-encoded RNA positive.
The sensitivity of EBV DNA in the detection of tumors regrowing from an irradiated site is much lower than that from a radiation-naïve site. Although plasma EBV DNA is very effective in detecting distant metastatic relapse of NPC, it cannot be relied on as the sole surveillance tool for detection of local relapse.
本研究旨在比较血浆EBV DNA在检测放疗后局部复发性鼻咽癌(NPC)、放疗后远处转移性NPC和初诊NPC中的敏感性。
采用实时定量PCR系统对24例放疗后局部复发的NPC患者的血浆EBV DNA水平进行评估。将结果与140例新诊断NPC患者队列以及25例远处转移复发患者的结果进行比较。对于血浆EBV DNA水平检测不到的局部复发肿瘤和新诊断肿瘤,也评估了EBV编码RNA的阳性情况。
与相同分期的初诊肿瘤相比,放疗后局部复发肿瘤的血浆EBV DNA可检测率显著降低[Ⅰ-Ⅱ期肿瘤:12例中的5例(42%)对51例中的47例(92%),P = 0.0002;Ⅲ-Ⅳ期肿瘤:12例中的10例(83%)对89例中的88例(99%),P = 0.01;Fisher精确检验],与远处转移复发相比[24例中的15例(63%)对25例中的24例(96%),P < 0.02;Fisher精确检验]。可检测到EBV DNA的患者中,局部复发肿瘤的EBV DNA中位水平也显著低于初诊肿瘤。所有血浆EBV DNA水平检测不到的相关肿瘤组织样本(如有)均为EBV编码RNA阳性。
EBV DNA在检测放疗部位复发肿瘤方面的敏感性远低于初诊部位。虽然血浆EBV DNA在检测NPC远处转移复发方面非常有效,但不能仅依靠它作为检测局部复发的唯一监测工具。